English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

SIR—Treatment with intravenous tissue plasminogen activator (t-PA) in acute ischaemic stroke has been shown to improve outcome [1]. Little is known regarding the safety and efficacy of this treatment in patients aged 80 years and older, because this age group was underrepresented in clinical trials [1–4]. The NINDS trial [1] was the only trial without age limit and only 7% (n = 42) of the included patients were older than 80 years. However, about 30% of admitted ischaemic stroke patients are older than 80 years [5]. A number of previous observational studies compared the outcome of t-PA treatment in patients older than 80 years with their younger counterparts [6–12], and a recent systemic review suggested that t-PA is safe in older patients, despite a higher 3-month mortality and a less favourable functional outcome [13]. In this study, we compared the safety and outcome of t-PA treatment in patients aged 80 years and older with their younger counterparts in a prospective cohort from the University Medical Center Groningen (UMCG). In contrast to most previous studies, we not only investigated the 3month mortality but we also compared the early in-hospital mortality at 7 days between the two groups.

age and ageing

Routine thrombolysis with intravenous tissue plasminogen activator in acute ischaemic stroke patients aged 80 years or older: a single centre experience